EFFECT OF RETROVIRAL LONG TERMINAL REPEAT (LTR)-CONTAINING TRANSGENES ON THYMIC LYMPHOMA INDUCTION IN FVB/N MICE NEONATALLY TREATED WITH AZACYTIDINE (MEETING ABSTRACT)

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

EFFECT OF RETROVIRAL LONG TERMINAL REPEAT (LTR)-CONTAINING TRANSGENES ON THYMIC LYMPHOMA INDUCTION IN FVB/N MICE NEONATALLY TREATED WITH AZACYTIDINE (MEETING ABSTRACT)

Proc Annu Meet Am Assoc Cancer Res; 33:A1100 1992. Unique Identifier : AIDSLINE ICDB/92683623
Wang TH; Yang WK; Saavedra HI; Yang DM; Popp DM; Hoyt PR; Ch'ang LY; Yang MY; Biology Div., Oak Ridge Natl. Lab., Oak Ridge, TN 37831

Abstract: In an attempt to activate the ecotropic LTR-containing transgene in FVB/N mice, we have found that neonatal injections of azacytidine can cause high incidence of thymic lymphomas in the transgenic mice at 3 to 7 mo of age, with massive involvement of thymus and other lymphoid tissues, as well as, tumor-cell infiltration in the lung, kidney, liver and other organs. FVB/N mice without transgenes were also susceptible to thymoma induction by the same treatment. However, immunofluorescence-cytometric analysis of primary thymomas revealed mainly immature patterns of T-cell development with considerable variation in surface antigen expression, with a tendency of CD8 greater than CD4 expression in lymphoma cells from the LTR transgenic mice, and CD4 greater than CD8 expression in those from control FVB/N mice. The thymoma-derived blast cells in in vivo cultures also showed the similar differences of CD8/CD4 expression.

Keywords: Animal Animals, Newborn Azacitidine/*TOXICITY Carcinogens/*TOXICITY CD4-CD8 Ratio Lymphoma/*CHEMICALLY INDUCED/*GENETICS/IMMUNOLOGY/PATHOLOGY Mice Mice, Inbred Strains Mice, Transgenic *Repetitive Sequences, Nucleic Acid Retroviridae/*GENETICS T-Lymphocyte Subsets/IMMUNOLOGY Thymus Neoplasms/*CHEMICALLY INDUCED/*GENETICS/IMMUNOLOGY/ PATHOLOGY Tumor Cells, Cultured ABSTRACT
920830
M9281083

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .